Yousif Capital Management LLC Sells 444 Shares of Maximus, Inc. $MMS

Yousif Capital Management LLC reduced its position in shares of Maximus, Inc. (NYSE:MMS) by 2.2% in the second quarter, HoldingsChannel reports. The firm owned 20,059 shares of the health services provider’s stock after selling 444 shares during the quarter. Yousif Capital Management LLC’s holdings in Maximus were worth $1,408,000 as of its most recent filing with the Securities & Exchange Commission.

A number of other large investors have also recently made changes to their positions in MMS. GAMMA Investing LLC grew its stake in shares of Maximus by 67.1% during the 1st quarter. GAMMA Investing LLC now owns 732 shares of the health services provider’s stock valued at $50,000 after acquiring an additional 294 shares during the period. Blue Trust Inc. grew its stake in shares of Maximus by 32.8% during the 1st quarter. Blue Trust Inc. now owns 1,228 shares of the health services provider’s stock valued at $84,000 after acquiring an additional 303 shares during the period. Universal Beteiligungs und Servicegesellschaft mbH bought a new position in shares of Maximus during the 1st quarter valued at approximately $2,115,000. Janney Montgomery Scott LLC grew its stake in shares of Maximus by 70.5% during the 1st quarter. Janney Montgomery Scott LLC now owns 10,145 shares of the health services provider’s stock valued at $692,000 after acquiring an additional 4,196 shares during the period. Finally, Oppenheimer Asset Management Inc. grew its stake in shares of Maximus by 24.0% during the 1st quarter. Oppenheimer Asset Management Inc. now owns 6,461 shares of the health services provider’s stock valued at $441,000 after acquiring an additional 1,249 shares during the period. 97.21% of the stock is owned by hedge funds and other institutional investors.

Maximus Stock Performance

NYSE:MMS opened at $87.15 on Tuesday. The stock’s fifty day moving average is $87.56 and its 200 day moving average is $76.88. Maximus, Inc. has a fifty-two week low of $63.77 and a fifty-two week high of $93.73. The firm has a market capitalization of $4.91 billion, a PE ratio of 16.05 and a beta of 0.57. The company has a debt-to-equity ratio of 0.91, a quick ratio of 2.27 and a current ratio of 2.27.

Maximus (NYSE:MMS) last released its quarterly earnings results on Thursday, August 7th. The health services provider reported $2.16 earnings per share for the quarter, beating the consensus estimate of $1.39 by $0.77. Maximus had a return on equity of 24.44% and a net margin of 5.83%.The company had revenue of $1.35 billion for the quarter, compared to analyst estimates of $1.29 billion. During the same quarter in the prior year, the firm posted $1.74 EPS. Maximus’s quarterly revenue was up 2.5% compared to the same quarter last year. Maximus has set its FY 2025 guidance at 7.350-7.550 EPS. On average, sell-side analysts anticipate that Maximus, Inc. will post 6.15 earnings per share for the current year.

Maximus Dividend Announcement

The firm also recently announced a quarterly dividend, which will be paid on Monday, December 1st. Shareholders of record on Friday, November 14th will be paid a $0.30 dividend. The ex-dividend date is Friday, November 14th. This represents a $1.20 dividend on an annualized basis and a yield of 1.4%. Maximus’s dividend payout ratio (DPR) is presently 22.10%.

Insiders Place Their Bets

In other Maximus news, insider Michelle F. Link sold 1,610 shares of the stock in a transaction on Wednesday, October 1st. The stock was sold at an average price of $90.86, for a total value of $146,284.60. Following the sale, the insider owned 13,508 shares in the company, valued at $1,227,336.88. This trade represents a 10.65% decrease in their ownership of the stock. The transaction was disclosed in a document filed with the SEC, which is available at this hyperlink. 1.60% of the stock is currently owned by insiders.

Analyst Upgrades and Downgrades

A number of research analysts recently issued reports on the company. Weiss Ratings upgraded Maximus from a “hold (c+)” rating to a “buy (b-)” rating in a research note on Wednesday, October 8th. Zacks Research upgraded Maximus from a “hold” rating to a “strong-buy” rating in a research note on Tuesday, August 26th. One research analyst has rated the stock with a Strong Buy rating and two have given a Buy rating to the company’s stock. According to data from MarketBeat, the stock currently has a consensus rating of “Buy” and a consensus target price of $90.00.

About Maximus

Maximus, Inc operates as a provider of government services in the United States and internationally. It operates through three segments: U.S. Federal Services, U.S. Services, and Outside the U.S. The U.S. Services segment offers program eligibility support and enrollment; centralized multilingual customer contact centers, multichannel, and digital self-service options for enrollment; application assistance and independent health plan choice counseling; beneficiary outreach, education, eligibility, enrollment, and redeterminations; and person-centered independent disability, long-term sick, and other health assessments.